Trial for Fluid Replacement System and CIN Prevention

Share this article:
PLC Medical Systems, Inc., of Franklin, Mass., has received full approval for a U.S. pivotal trial to study the effectiveness of its RenalGuard System and associated therapy in the prevention of contrast-induced nephropathy (CIN).

RenalGuard is a fully automated fluid-replacement device intended for interventional cardiology and radiology patients undergoing imaging procedures using contrast media.

The third most common cause of in-hospital acute renal failure, CIN is associated with increases in long-term mortality rates, major in-hospital adverse cardiac events, and the risk of having to undergo renal dialysis therapy.

Share this article:
You must be a registered member of RUN to post a comment.

More in FDA News

FDA to Lift Restrictions on Avandia for Diabetes

FDA to Lift Restrictions on Avandia for Diabetes

Not all experts are happy with granting wider access to the troubled medication, however.

FDA Approves Enlarged Prostate Urine Flow Device

FDA Approves Enlarged Prostate Urine Flow Device

UroLift system, a permanent implant, helps relieve blocked urine flow.

FDA Announces New Interactive Patient Network

FDA Announces New Interactive Patient Network

Interactive tool designed to educate patients and advocates about processes of drug development.